Responsible for this function: Centre Manager Yamila Torres Cleuren
The Centre has been buzzing with activity as we continue to forge powerful scientific collaborations and consortia. We’re thrilled to see the fruits of our labour with a continued partnership both nationally and internationally, reflected in significant funding for our projects. Our dynamic, interdisciplinary approach allows us to craft innovative projects across research groups, leveraging the diverse expertise available.
One of our greatest strengths is our cross-disease research. Breakthroughs in one area, such as PD, are being translated into advancements for ALS, dementia, and MS. This synergy has sparked the creation of new laboratory and clinical trial projects, thanks to the interactions between our research teams.
We have continued to make strides in securing European grants, which are pivotal for the long-term success of our research. Increasing the Centre’s visibility has been a key focus, ensuring our projects transcend national borders and enhance both our national and international collaborations, and not least, benefitting everyone living with these diseases.
A good example of our success is the European project “NADage”, which we are leading, with start-up in 2025. This project received funding from the ERA4HEALTH program “Nutribrain”. This funding is a great boost and a testament to Neuro-SysMed’s growing international reputation.
In 2024, we continued to attract funding from various sources. Our Regional Health Authorities (Helse Vest) supported us with two PhD projects, one postdoc, a clinical fellowship grant, 3 open project support grants for our clinical and translational projects, and one strategic research grant of 20 MNOK. KLINBEFORSK funded our first national dementia trial with 25 MNOK, while the Norwegian Research Council provided commercialisation funding to two new projects. Additionally, the UiB, private donors, patient organisations, and foundations have provided crucial support, especially for projects in their start-up phase.